Deep vein thrombosis
366 results
239 - 338
ACCP 2016: updated guidelines for VTE- Fixed-dose, subcutaneous, unfractionated heparin effective for VTE
- Tinzaparin no better than warfarin in preventing recurrent VTE in adults with cancer
Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty: Cochrane systematic review- Rutosides for prevention of post-thrombotic syndrome: Cochrane systematic review
COVID-19 and other coronavirus infections - Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins: Cochrane systematic review
- Vena caval filters for the prevention of pulmonary embolism
- Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
- Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
- Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
- Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement: Cochrane systematic review
- Compression therapy for treating post‐thrombotic syndrome
- YEARS clinical decision tool decreases CT angiography in patients with suspected PE
- YEARS algorithm helpful for evaluating suspected PE in pregnant women
- Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
- Lenalidomide effective for relapsed multiple myeloma
- Femoral lines not associated with increased risk of bloodstream infections
- Edoxaban noninferior to warfarin for venous thromboembolism anticoagulation
- Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases
- Postoperative tamoxifen for ductal carcinoma in situ
- Risk‐reducing medications for primary breast cancer: a network meta‐analysis
- Lower leg fractures
- Statins for primary prevention of venous thromboembolism
- Vascular closure devices for femoral arterial puncture site haemostasis
- Compression therapy for prevention of post‐thrombotic syndrome
- Adder (Vipera berus) bite
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Pulmonary embolism rule-out criteria reduces the need for CT pulmonary angiography in low-risk patients (PERC)
- Thromboprophylaxis with apixaban prevents VTE in high-risk cancer patients (AVERT); jury still out on rivaroxaban (CASSINI)
- Apixaban is noninferior to dalteparin for venous thromboembolism associated with cancer
- Prevalence of pulmonary embolism is 5.9% in patients with COPD who are hospitalized with acute respiratory symptoms
- Apixaban slightly more effective and safe than warfarin, but more expensive
- Small benefit to extended treatment with apixaban in selected patients with VTE
- Perioperative bridging anticoagulation unhelpful for invasive procedures
- Anticoagulants versus non‐steroidal anti‐inflammatories or placebo for treatment of venous thromboembolism
- Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period
- Treatment for femoral pseudoaneurysms: Cochrane systematic review
- Positioning and spinal bracing for pain relief in metastatic spinal cord compression in adults
- Short term benefits for laparoscopic colorectal resection
- Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta‐analysis
- Pulmonary embolism
- Low-molecular-weight heparins vs. standard heparin for acute ischaemic stroke
- Interventions for lowering plasma homocysteine levels in dialysis patients
- Anticoagulants for people hospitalised with COVID‐19
- Optimal treatment of acute venous thromboembolism
- Caesarean section versus vaginal delivery for preterm birth in singletons
- Self‐monitoring and self‐management of oral anticoagulation
- Warfarin initiation nomograms for venous thromboembolism: Cochrane systematic review
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Risk of ischaemic stroke in persons with migraine without aura using combined hormonal contraception
- Continuous vs. intermittent physiological monitoring for acute stroke
- Peripherally inserted central catheter design and material for reducing catheter failure and complications
- Injection sclerotherapy for varicose veins
- Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
- Treatment of gestational diabetes mellitus to a tighter glycemic target is not beneficial
- D-dimer can identify high-risk group for extended anticoagulation (PROLONG)
- General versus loco‐regional anesthesia for endovascular aortic aneurysm repair
- Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery
- Extended use of dabigatran no better than warfarin for high-risk pts after VTE; no net benefit vs placebo for avg-risk pts
- Rutosides for treatment of post-thrombotic syndrome: Cochrane systematic review
- Statins for primary prevention of venous thromboembolism: Cochrane systematic review
- Antifibrinolytic drugs for acute traumatic injury: Cochrane systematic review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures
- Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
- Oral antiplatelet therapy for acute ischaemic stroke
- Venous insufficiency of the lower limbs
- Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism
- Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults: Cochrane systematic review
- 10 days enoxaparin better than 35 days rivaroxaban for medical inpatient thromboprophylaxis (MAGELLAN)
- Outpatient versus inpatient treatment for acute pulmonary embolism
- Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
- Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other non-traumatic diseases: Cochrane systematic review
- Guideline for Dx of PE in pregnant women
- Prophylactic anticoagulants for non‐hospitalised people with COVID‐19
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
- Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears)
- Interventions for varicose veins and leg oedema in pregnancy
- Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism
- Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease
- Risk of a venous thromboembolism during the postpartum period
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
- Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders: Cochrane systematic review
- Anticoagulants versus antiplatelet agents for acute ischaemic stroke: Cochrane systematic review